AllSci News
Bayer to acquire Perfuse Therapeutics for USD 2.45b to expand ophthalmology pipeline with PER-001
Bayer has agreed to acquire South San Francisco-based Perfuse Therapeutics, Inc. for a total potential value of up to USD 2.45 billion, comprising a USD 300...
Clearmind seeks European patent for non-hallucinogenic neuroplastogen PTSD compounds
Clearmind Medicine Inc. (Vancouver, Canada), a clinical-stage biotech focused on neuroplastogen therapeutics, announced the filing of a European patent application covering novel…
ZYUS Life Sciences receives USPTO patent for cannabichromene pain management formulation
ZYUS Life Sciences Corporation (Canada), a clinical-stage company listed on the TSXV under the ticker ZYUS, received US Patent No. 12,616,704 from…
Scilex spins off ACEA Pharma to Phoenix Asia Holdings in USD 1b all-stock transaction
I need to flag a direct conflict between the two instruction sets provided.
Avalo Therapeutics' abdakibart meets primary endpoint in Phase II hidradenitis suppurativa trial
Avalo Therapeutics (Nasdaq: AVTX) reported that abdakibart, its anti-IL-1β monoclonal antibody, met the primary endpoint in the Phase II LOTUS trial in...
Cytokinetics' aficamten meets endpoints in Phase III non-obstructive cardiomyopathy trial, nudging ahead of BMS
Cytokinetics (Nasdaq: CYTK) reported that aficamten met both dual primary endpoints in the Phase III ACACIA-HCM trial in symptomatic non-obstructive...
Merck completes USD 2.7b acquisition of Terns Pharmaceuticals for BCR-ABL1 inhibitor TERN-701
Merck (NYSE: MRK) has completed the acquisition of Terns Pharmaceuticals, a US-based clinical-stage biopharmaceutical company, through an all-cash tender...
Pfizer's Q1'26 Earnings Call: Pivotal oncology readouts on track for mid-to-late 2026, Elrexfio meets endpoint
Pfizer held its Q1 2026 earnings conference call on May 5, 2026, with chief scientific officer Chris Boshoff signaling that the Phase III MagnetisMM-5 study...
Cytospire raises GBP 61m via Series A for gamma delta T-cell engagers
Cytospire Therapeutics, a London-based biotech developing multispecific immune cell engager antibodies, has closed an oversubscribed Series A financing...
Cellectar raises USD 140m in oversubscribed financing for oncology programs
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company based in Florham Park, New Jersey focused on targeted oncology...
Elaris acquires Matrivax C. difficile vaccine assets via equity stake and royalties deal
Vienna-based Elaris FlexCo has entered into an asset purchase agreement with US-based Matrivax Research & Development Corporation to acquire intellectual...
Johnson & Johnson's guselkumab demonstrates efficacy in Phase III perianal fistulizing Crohn's disease trial
Johnson & Johnson (NYSE: JNJ) reported that guselkumab (Tremfya) met the primary endpoint of combined fistula remission in the Phase III FUZION study in...
BrightGene posts 19.3% weight reduction in Phase III obesity trial for GLP-1/GIP injection
BrightGene Bio-Medical Technology Co., Ltd. (688166.SH) reported that BGM0504, its GLP-1/GIP dual receptor agonist, reduced body weight by a mean of 19.3%...
Apertura Gene Therapy and TSC Alliance collaborate on AAV gene therapy for tuberous sclerosis complex
Apertura Gene Therapy has entered a collaboration agreement with the TSC Alliance, a Silver Spring, Maryland-based patient advocacy organization founded in...
Pershing Square Sohn Cancer Alliance awards USD 9m to 13 early-career cancer researchers
The Pershing Square Sohn Cancer Research Alliance has awarded USD 9 million across 13 early-career investigators through the 2026 Pershing Square Sohn...
The AllSci Brief
Free, systematic R&D and deal news. Daily.